Amicrobial pustulosis of the folds (APF) is a recently described entity characterized by relapsing pustular lesions predominantly involving the cutaneous flexures and scalp. This disease typically occurs in association with systemic lupus erythematosus and a variety of other autoimmune diseases. We here describe an APF-like pustular eruption predominantly affecting the scalp, face and trunk, occurring during long-term infliximab treatment for Crohn’s disease. Immunohistochemical staining of skin biopsy specimens for myxovirus resistance protein A, a marker for type 1 interferon-inducible proteins, showed increased staining in the epidermis and dermal mononuclear inflammatory infiltrate. Our observation further extends the spectrum of cutaneous adverse reactions potentially related to anti-tumor necrosis factor-α, the clinical context in which APF can occur as well as its clinical presentations.

Keywords:
Amicrobial pustulosis, Lupus erythematosus, Infliximab, Neutrophilic dermatoses, Cutaneous lupus, Tumor necrosis factor-α inhibitor
1.
Crickx B: Pustulose amicrobienne et lupus érythémateux systémique. Journées Dermatologiques de Paris, Paris 1991, C11.
2.
Kerl K, Masouyé I, Lesavre P, Saurat JH, Borradori L: A case of amicrobial pustulosis of the folds associated with neutrophilic gastrointestinal involvement with systemic lupus erythematosus. Dermatology 2005;211:356–359.
3.
Antille C, Frei M, Sorg O, Tran C, Kaya G, Masouyé I, Fontao L, Prins C, Saurat JH: Amicrobial pustulosis of the folds associated with auto-immune disorders: a case report with an analysis of cytokine expression profile in skin lesions of cutaneous neutrophilic lupus. Dermatology 2008;216:324–329.
4.
Lagrange S, Chowsidow O, Piette JC, Wechsler B, Godeau P, Frances C: A peculiar form of amicrobial pustulosis of the folds associated with systemic lupus erythematosus and other auto-immune diseases. Lupus 1997;6:514–520.
5.
Marzano AV, Capsoni F, Berti E, Gasparini G, Bottelli S, Caputo R: Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity? Dermatology 1996;193:88–93.
6.
Marzano AV, Ramoni S, Caputo R: Amicrobial pustulosis of the folds. Dermatology 2008;216:305–311.
7.
Saiag P, Blanc F, Marinho E, De la Blanchardière A, Leconte I, Cocheton JJ, Tulliez M: Amicrobial pustulosis and systemic lupus erythematosus: a case. Ann Dermatol Venereol 1993;120:779–781.
8.
Stefanidou MP, Kanavaros PE, Stefanaki KS, Tosca AD: Amicrobial pustulosis of the folds: a cutaneous manifestation associated with connective tissue disease. Dermatology 1998;197:394–396.
9.
Kuyama M, Fujimoto W, Kambara H, Egusa M, Saitoh M, Yamasaki O, Maehara K, Ohara A, Arata J, Iwatsuki K: Amicrobial pustular dermatosis in two patients with immunological abnormalities. Clin Exp Dermatol 2002;27:286–289.
10.
Lopez-Navarro, Alcaide A, Gallego E, Herrera-Acosta E, Gallardo M, Bosch RJ, Herrera E: Amicrobial pustulosis of the folds associated with Hashimoto’s thyroiditis. Clin Exp Dermatol 2009;34:e561–e563.
11.
Lipsker D, Saurat JH: Neutrophilic cutaneous lupus erythematosus: at the edge between innate and acquired immunity? Dermatology 2008;216:283–286.
12.
De Gannes G, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223–231.
13.
Laga AC, Vleugels RA, Qureshi AA, Velazquez EF: Histopathologic spectrum of psoriasiform skin reactions associated with tumour necrosis factor-alpha inhibitor therapy: a study of 16 biopsies. Am J Dermatol 2010;32:568–573.
14.
Seneschal J, Milpied B, Vergier B, Lepreux S, Schaverbeke T, Taieb A: Cytokine imbalance with increased production of interferon- alpha in psoriasiform eruptions associated with anti-tumour necrosis factor-alpha treatments. Br J Dermatol 2009;161:1081–1088.
15.
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DPM: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology biologics register. Ann Rheum Dis 2009;68:209–215.
16.
Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ: Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009;61:486–504.
17.
Vazquez J, Almagro M, del Pozo J, Fonseca E: Neutrophilic pustulosis and ulcerative colitis. J Eur Acad Dermatol Venereol 2003;17:77–79.
18.
Callen JP: Pustular eruptions in systemic diseases. Clin Dermatol 2000;18:349–353.
19.
Sarkany R, Burrows NP, Grant JW, Pye RJ, Norris PG: The pustular eruption of ulcerative colitis. Br J Dermatol 1998;138:365–366.
20.
Wenzel J, Tuting T: An IFN-associated cytotoxic cellular immune response against viral, self- or tumor antigens is a common pathogenic feature in ‘interface dermatitis’. J Invest Dermatol 2008;128:2392–2402.
21.
Kelly-Scumpia KM, Scumpia PO, Delano MJ, Weinstein JS, Cuenca AG, Wynn JL, Moldawer LL: Type 1 interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL 10. J Exp Med 2010;207:319–326.
22.
Kerbleski JF, Gottlieb AB: Dermatological complications and safety of anti-TNF treatments. Gut 2009;58:1033–1039.
23.
Flendrie M, Vissers WHPM, Creemer MCW, de Jong Elke MGJ, van de Kerkhof PC, van Riel PLCM: Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666–R676.
24.
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert H, Audring H, Kary S, Burmester GR, Sterry W, Worm M: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007;156:486–491.
25.
Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker M, Massaroti EM, Bush ML: Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad 2009;61:104–111.
26.
Fernandez-Torres R, Paradela S, Valbuena L, Fonseca E: Infliximab induced lichen planopilaris. Ann Pharmacother 2010;44:1501–1503.
27.
Deng A, Harvey V, Sina B, Strobel D, Badros A, Jukins-Hopkins J, Samuels A, Oghilikhan M, Gaspari A: Interstitial granulomatous dermatitis associated with the use of tumour necrosis factor alpha inhibitors. Arch Dermatol 2006;142:198–202.
28.
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA: Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567–570.
29.
Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Bournier P, Clabaut A, Lok C: Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology 2010;220:234–237.
30.
Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R: Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007;26:2205–2206.
31.
Williams EL, Gadola S, Edwards CJ: Anti-TNF-induced lupus. Rheumatology 2009;48:716–720.
32.
Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadradro MJ, Khamashta MA: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242–251.
33.
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group: Autoimmune diseases induced by biological agents: a double-edged sword. Autoimmun Rev 2010;9:188–193.
34.
Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J: Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146:780–784.
35.
Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, Morini JP, Gorin I, Ziza JM, Avril MF, Dupin N: Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010;221:201–205.
36.
Daulat S, Detweiler JG, Pandya AG: Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 2009;23:483–484.
37.
Leombruno JP, Einarso TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136–1145.
38.
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D: Cancer risk with tumor necrosis factor alpha inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119–130.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.